B · Normal
[Balitianheng: The first subject has been enrolled in the T-Bren phase III clinical trial] On September 29, Baileytianheng (688506.SH) announced that the company's independently developed injectable T-Bren (HER2ADC) has completed the first subject enrollment in the phase III randomized controlled clinical trial comparing BL-M07D1 with physician-selected chemotherapy in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. As of now, T-Bren is conducting 20 clinical trials at home and abroad, and two of its indications have been included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration.
Comments